Genelux (GNLX) Q3 2024 earnings summary

Executive summary

• Focused on developing oncolytic viral immunotherapies for aggressive solid tumors, with lead candidate Olvi-Vec in Phase 3 for ovarian cancer and Phase 2 for lung cancer, and ongoing trials in SCLC and PRROC.

• Initiated a US-based Phase 2 trial (VIRO-25) for recurrent advanced/metastatic NSCLC using Olvi-Vec, with combination platinum-doublet chemotherapy and immune checkpoint inhibitor.

• No products approved for sale; minimal revenue recognized from licensing agreements.

• Interim data from SCLC trial expected by end of 2024; topline results from PRROC and NSCLC trials anticipated in 2025.

• Cash, cash equivalents, and investments of $35.1 million expected to fund operations into Q1 2026.

Financial highlights

• Revenue for the nine months ended September 30, 2024 was $8,000, down from $170,000 in the prior year period.

• R&D expenses increased to $12.5 million for the nine months and $4.1 million in Q3 2024, driven by higher compensation, stock-based compensation, outsourced manufacturing, and clinical trial costs.

• G&A expenses rose to $9.5 million for the nine months and $2.9 million in Q3 2024, mainly due to increased stock compensation and consulting costs.

• Net loss for the nine months ended September 30, 2024 was $20.9 million, with a Q3 2024 net loss of $6.5 million.

• Shareholders' equity increased to $33.1 million as of September 30, 2024, from $19.5 million at December 31, 2023.

Outlook and guidance

• Cash and investments expected to last into the first quarter of 2026, but substantial additional funding will be needed for continued development and commercialization.

• Interim SCLC trial data expected by end of 2024; PRROC and NSCLC trial data releases anticipated in 2025.

• Anticipates continued increases in R&D and G&A expenses as clinical programs expand.